Evidence strength: Symptom-dependent, not universal
Prescribing a cannabis-based decoction, considering the low recovery rates of THC and CBD and, consequently, the high volume of preparation that the patient would have to ingest, should not be the first choice for cannabis-based therapies
Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease
Patients should be monitored for any adverse reactions, and adjustments in dosage may be made based on individual response and tolerance
I personally would seek out making other changes before Ozempic, but I think people have the right to make decisions about their own bodies. In the comments section of her TikTok video, many users seemed to agree with Moranos take on the weight-loss drug
This is where Listen Labs can help
